CTLA4 and cancer: Immune checkpoint blockade including antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) proteins, have demonstrated anti-cancer activity in multiple cancer types [1].